AI制药为何仍不能颠覆药物研发?专家:生物模型发展滞后

第一财经
Jul 24

AI制药似乎从不缺乏高光时刻——近半年,国内外数款AI设计的管线迈进Ⅲ 期临床。但随着首批AI药物的研发历程几近走完,产业界与资本市场对于 “AI能做什么”的预期已悄然回归至一个更趋冷静的轨道上。  一个共识正在形成:AI带来的“快”,并不必然带来“省”;AI药的最终身价,归根结底要看它能够带来多少临床价值,而不仅仅依靠其算法标签。从“设计分子”走向“解决未满足临床需求”,AI制药要走的路还很长。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10